Glycopeptides as Potential Interventions for COVID-19

Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) The outbreak emerged from Wuhan, China, and later spread throughout the world Until the first week of May 2020, over 3 7 million cases had been reported worldwide and more than 258,000 had died due to the disease So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2;however, new interventions are likely to require months to years to develop Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2 Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2 Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARSCOV2 These drugs block proteolysis of polyprotein a/b with replicase and transcription domains Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2